Diffuse large B-cell lymphoma(DLBCL),the most common subtype of non-Hodgkin lymphoma,is highly heterogeneous and invasive.Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide...Diffuse large B-cell lymphoma(DLBCL),the most common subtype of non-Hodgkin lymphoma,is highly heterogeneous and invasive.Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisone treatment,approximately one-third of patients still have a poor prognosis.Many immune-targeted drugs,such as bispecific T-cell engagers and CAR T-cell therapy,have been proven effective for refractory and relapsed patients.This article reviews the progress of immune targeted therapy for DLBCL.展开更多
基金Grant ZC20171 from Tianjin Health Science and Technology ProjectTY is funded by Grant 81800148 from National Natural Science Foundation of China(NSFC).
文摘Diffuse large B-cell lymphoma(DLBCL),the most common subtype of non-Hodgkin lymphoma,is highly heterogeneous and invasive.Although the majority of DLBCL patients show a good response to rituximab plus cyclophosphamide,doxorubicin,vincristine,and prednisone treatment,approximately one-third of patients still have a poor prognosis.Many immune-targeted drugs,such as bispecific T-cell engagers and CAR T-cell therapy,have been proven effective for refractory and relapsed patients.This article reviews the progress of immune targeted therapy for DLBCL.
